Clinical trials: Hematopoiesis
JAK2 Mutation
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm.
- Trial name
- NCT07249840
- Testing
- Ropeginterferon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
Combination Therapy of Severe Aplastic Anemia
This study will test the safety and effectiveness of a combination of three drugs in treating severe aplastic anemia and preventing its recurrence.
- Trial name
- NCT00001964
- Testing
- Cyclosporine A, ATG, MMF
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerosis, Coronary, Emotional Stress
Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability
Emotional stress is associated with future cardiovascular events. However, the biological interconnection between brain emotional neural activity and acute plaque instability is not fully understood.
- Conditions
- Atherosclerosis, Coronary, Emotional Stress, Inflammation, Hematopoiesis
- Trial name
- NCT04853511
- Testing
- OCT-FLIM (optical coherence tomography-fluorescence life time)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Korea University Guro Hospital
DNMT3A Gene Mutation
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under…
- Trial name
- NCT07188740
- Testing
- Metformin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelodysplastic Syndrome
Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?
Researchers from Memorial Sloan-Kettering Cancer Center, in collaboration with The New York Presbyterian Hospital-Weill Medical College of Cornell University, are conducting a study of a medicinal mushroom extract called Maitake…
- Trial name
- NCT01099917
- Testing
- Maitake
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colchicine, Coronary Atherosclerosis Management
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS…
- Conditions
- Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- NCT07362966
- Testing
- Colchicine 0.5 mg orally once daily for 12 months., SoC therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Northern Hospital
Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse
Alemtuzumab to Treat Severe Aplastic Anemia
This study will evaluate the safety and usefulness of a new immunosuppressive drug, alemtuzumab (Campath ), in patients with severe aplastic anemia (SAA).
- Trial name
- NCT00195624
- Testing
- Alemtuzumab (Campath ), Cyclosporine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe/Moderate Coronavirus, Chronic Myelomonocytic Leukemia
Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)
The purpose of this study is to provide new insights into the pathophysiology of emergency hematopoiesis detected in severe COVID-19 patients.
- Conditions
- Severe/Moderate Coronavirus, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Old Age
- Trial name
- CALPRO (NCT04953312)
- Testing
- Blood samples
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers.
- Trial name
- NCT00003095
- Where
- 83 sites in United States
- Volunteers
- 26 people
- Sponsor
- SWOG Cancer Research Network
PTSD, Trauma
PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients
Project 3 of the PPG grant "Stress and Atherosclerotic Plaque Macrophages A Systems Biology Approach," funded by the NHLBI, examines the relationship between psychosocial stress and atherosclerotic inflammation, cell…
- Conditions
- PTSD, Trauma, Healthy
- Trial name
- NCT03279393
- Testing
- fluorodeoxyglucose (FDG)-PET/MRI
- Where
- 2 sites in United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Zahi Fayad
Severe Aplastic Anemia (SAA)
Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Background: Eltrombopag is a drug being tested for treating severe aplastic anemia. It can help improve blood counts in these patients.
- Trial name
- NCT01891994
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Osteoporosis, Osteoarthritis, Hip
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations.
- Conditions
- Osteoporosis, Osteoarthritis, Hip, Hip Fractures, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- NCT05246813
- Testing
- Blood and bone marrow cell collection
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Imelda Hospital, Bonheiden
Severe Aplastic Anemia
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
- Trial name
- BMT CTN CureAA (NCT06517641)
- Testing
- Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
- Where
- 25 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin
Hematologic Diseases
Evaluation, Treatment, and Training for Patients With Blood Disorders
This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and…
- Trial name
- NCT00001397
- Where
- United States
- Volunteers
- 1,452 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immune System Diseases, Autoimmune Diseases
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic)…
- Conditions
- Immune System Diseases, Autoimmune Diseases, Inflammation, Autoinflammatory Diseases
- Trial name
- CHIS (NCT05969821)
- Testing
- observational cohort study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Abnormal Hematopoiesis, Allogenic Disease
Graft-versus-host Disease Associated Myelosuppression
The objective is to measure the frequency, functionality and phenotype of bone marrow-derived mesenchymal stromal cells in patients after allogeneic hematopoietic stem cell transplantation.
- Conditions
- Abnormal Hematopoiesis, Allogenic Disease, Graft vs Host Disease
- Trial name
- NCT02829216
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technische Universität Dresden
ACS, Clonal Hematopoiesis of Indeterminate Potential
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation
In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete…
- Conditions
- ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation
- Trial name
- CHIP-RETENTION (NCT04987268)
- Testing
- clonal hematopoiesis of indeterminate potential
- Where
- China
- Volunteers
- 1,029 people
- Sponsor
- Shenyang Northern Hospital
Aplastic Anemia, Neutropenia
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Background: Severe aplastic anemia (SAA) can lead to problems with bone marrow health and result in low blood cell counts, which require frequent transfusions.
- Conditions
- Aplastic Anemia, Neutropenia, Pancytopenia, Severe Aplastic Anemia
- Trial name
- NCT01193283
- Testing
- Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
To Investigate the Effect of CHIP on Renal Insufficiency in AMI Patients
Clonal Hematopoiesis on Prognosis in Patients With Myocardial Infarction
This is an observational study without intervention. It is planned to include 500 patients with AMI from October 2023 to July 2026.The study was divided into three parts.
- Trial name
- NCT06156319
- Testing
- No intervention
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Yang Jing